Sarepta Therapeutics, Inc. 8-K Filing

Sarepta Therapeutics, Inc. has entered into exchange agreements to exchange approximately $291.4 million of its 1.25% Convertible Senior Notes due 2027 for approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 and $31.6 million in cash. These new notes were issued on December 18, 2025, under an indenture supplemented by a First Supplemental Indenture. The new notes are part of the same series as previously issued 2030 notes, bringing the total aggregate principal amount of the 4.875% Convertible Senior Notes due 2030 to approximately $893.4 million. This transaction involves an entity affiliated with a board member, Michael Chambers. The filing also details the terms of the new notes, including restrictions on transfer and conversion, and incorporates by reference the First Supplemental Indenture as an exhibit. This action is classified as an entry into a material definitive agreement and creation of a direct financial obligation.